Joe McKendrick
Eastern Health · 23 works · 2,725 citations · h-index 10
Top works
- Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
- Lean body mass, body surface area and epirubicin kinetics
- Metastatic urachal cancer responding to FOLFOX chemotherapy.
- Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer
- Nonseminomatous germ cell tumor with very high serum human chorionic gonadotropin
- Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era
- Liver metastases in germ cell cancer: defining a role for surgery after chemotherapy
- A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer
- Tolerability of Accelerated Chest Irradiation and Impact on Survival of Prophylactic Cranial Irradiation in Patients with Limited-stage Small Cell Lung Cancer: Review of a Single Institution's Experience
- Single dose rasburicase in tumor lysis: One hospital's experience
- Evaluation of the Effect of Aflibercept (Z) on Os by Timing of 1st Line Disease Progression: A Post-Hoc Analysis of the Velour Trial
- O ral C apecitabine C ompared W ith I ntravenous Fluorouracil P lus L eucovorin i n P atients W ith M etastatic Colorectal C ancer: R esults o f a L arge P hase I II S tudy
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effi cacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
- 6050 POSTER A 12-week Regimen With Interdigitating FOLFOX Chemotherapy and Pelvic Chemoradiation for Simultaneous Primary and Metastatic Rectal Cancer
- Peripheral Blood Stem Cell (PBSC) Mobilization in Patients with Multiple Myeloma: Low Dose Versus Intermediate Dose Cyclophosphamide.
- Capecitabine
- Biological Features of Response to Immune Checkpoint Inhibitor and Rituximab Priming in Diffuse Large B-Cell Lymphoma
- P-603 Symptom response following high dose (HD) palliative radiotherapy (RT) plus concurrent weekly vinorelbine (V) and cis-platinum (C) in patients with locally advanced and metastatic non-small cell lung cancer (NSCLC): Results of a phase-I study